靶向与系统认知自由手引导经会阴穿刺活检:系统活检是否仍有必要?
研究纳入282例接受联合系统与靶向经会阴前列腺穿刺的患者,评估靶向活检是否仍需追加系统活检以避免漏诊临床显著前列腺癌,并分析仅取靶向象限活检的获益。结果显示靶向活检单独检出88%的临床显著癌,系统活检额外检出12%,且漏诊比例随MRI Likert评分升高而降低。
要点
- 靶向活检单独检出88%的临床显著癌(Gleason≥3+4),系统活检额外检出12%。
- Likert评分3、4、5的靶向检出率分别为73%、92%、100%。
- 仅追加同象限系统活检可检出靶向漏诊显著癌的75%(18/24)。
核心结论
- 系统活检在评估所有转诊前列腺穿刺患者时仍是重要工具,但MRI怀疑度越高需求越低。
- Likert评分5的患者可能无需系统穿刺,除非需要代表性周围活检用于其他特定治疗。
研究设计与样本
- 单中心回顾性分析282例接受联合系统映射与靶向经会阴前列腺穿刺的患者。
- 使用PrecisionpointTM设备,在局部麻醉(58%,163/282)、静脉镇静(12%,34/282)或全身麻醉(30%,85/282)下进行。
- 平均获取24(范围5-42)条系统穿刺芯和4.2(范围1-11)条靶向穿刺芯。
主要发现
- 患者平均年龄66.8(范围36-80)岁,中位PSA 7.4(范围0.91-116)ng/mL,平均前列腺体积45.8(范围13-150)mL。
- 82%(230/282)为初次活检,18%(52/282)为监测患者。
- 69%(195/282)检出临床显著病(Gleason≥3+4),84%(237/282)检出任何癌(Gleason≥3+3)。
- 靶向活检单独检出88%(171/195)的临床显著病,系统活检额外检出12%(24/195)。
- Likert评分3、4、5的靶向检出率分别为73%、92%、100%。
关键数值与推荐
- 临床显著癌定义为Gleason评分≥7。
- MRI使用Likert量表报告。
- 靶向活检加同象限系统活检检出靶向漏诊显著癌的75%(18/24)。
临床怎么用
- 对所有转诊前列腺穿刺患者,系统活检仍应作为评估工具。
- MRI Likert评分5的患者可考虑省略系统穿刺,除非需要代表性周围活检用于局灶治疗或手术规划。
局限性
- 需要更多前瞻性研究全面评估省略系统活检的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether targeted cognitive freehand-assisted transperineal biopsies using a PrecisionpointTM device still require additional systematic biopsies to avoid missing clinically significant prostate cancer, and to investigate the benefit of a quadrant-only biopsy approach to analyse whether a quadrant or extended target of the quadrant containing the target only would have been equivalent to systematic biopsy. PATIENTS AND METHODS: Patients underwent combined systematic mapping and targeted transperineal prostate biopsies at a single institution. Biopsies were performed using the Precisionpoint device (Perineologic, Cumberland, MD, USA) under either local anaesthetic (58%, 163/282), i.v. sedation (12%, 34/282) or general anaesthetic (30%, 85/282). A mean (range) of 24 (5-42) systematic and 4.2 (1-11) target cores were obtained. Magnetic resonance imaging (MRI) scans were reported using the Likert scale. Clinically significant cancer was defined as Gleason 7 or above. Histopathological results were correlated with the presence of an MRI abnormality within a spatial quadrant and the other adjoining or non-adjoining (opposite) quadrants. Histological concordance with radical prostatectomy specimens was analysed. RESULTS: A total of 282 patients were included in this study. Their mean (range) age was 66.8 (36-80) years, median (range) prostate-specific antigen level 7.4 (0.91-116) ng/mL and mean prostate volume 45.8 (13-150) mL. In this cohort, 82% of cases (230/282) were primary biopsies and 18% (52/282) were patients on surveillance. In all, 69% of biopsies (195/282) were identified to have clinically significant disease (Gleason ≥3 + 4). Any cancer (Gleason ≥3 + 3) was found in 84% (237/282) of patients. Of patients with clinically significant disease, the target biopsies alone picked up 88% (171/195), with systematic biopsy picking up the additional 12% (24/195) that the target biopsies missed. This altered with Likert score; 73% of Likert score 3 disease was detected by target biopsy, 92% of Likert score 4 and 100% of Likert score 5. Target biopsies with additional same-quadrant-only systematic cores picked up 75% (18/24) of significant cancer that was missed on target only, found in the same quadrant as the target. CONCLUSION: Systematic biopsy is still an important tool when evaluating all patients referred for prostate biopsy, but the need is decreased with increasing suspicion on MRI. Patients with very high suspicion of prostate cancer (Likert score 5) may not require systematic cores, unless representative surrounding biopsies are required for other specific treatments (e.g. focal therapy, or operative planning). More prospective studies are needed to evaluate this in full.
引用
- Neale A, Stroman L, Kum F, et al. Targeted and systematic cognitive freehand-guided transperineal biopsy: is there still a role for systematic biopsy? BJU Int. 2020. PMID: 32320126. doi:10.1111/bju.15092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。